11/19/2013 | CVLM | Onyx Pharmaceuticals calls all $35 million of 4% convertibles due 2016
|
8/26/2013 | CV | Market Commentary: Tesla convertibles move up in line before shares pare gains; Onyx 7 points over parity
|
7/1/2013 | CV | Market Commentary: Upcoming holiday weighs on liquidity in convertibles market; Intel active; Onyx rises
|
7/23/2012 | CV | Market Commentary: Convertibles mostly quiet: Kodak drops sharply after negative ruling; Onyx adds on hedge
|
7/2/2012 | CV | Market Commentary: Lincare jumps on hedged basis on Linde takeout; Amylin up outright on Bristol-Myers deal
|
6/22/2012 | CV | Market Commentary: Patriot Coal continues to weaken; Onyx extends gains; Royal Gold slips in line; K-V drops
|
6/21/2012 | CV | Market Commentary: Convertibles hold up despite slide in shares; Onyx surges on drug panel backing; AMR retraces 60
|
6/20/2012 | CV | Onyx convertible eyed after cancer drug gets backing of FDA panel
|
11/29/2011 | CV | Market Commentary: AMR collapses after bankruptcy filing; Transocean Cs improve; Onyx seen lower on hedge
|
7/27/2010 | CV | Market Commentary: Gilead opens higher, comes in; Onyx, ViroPharma in trade; AGCO in line; A&P bounces around
|
7/8/2010 | CV | Market Commentary: Convertibles 'better to buy'; Transocean paper sees strength; Hologic improves; Onyx quiet
|
10/12/2009 | CV | Market Commentary: Convertibles mostly quiet; Cameron, Nabors edge higher as oil rises; US Airways, AMR firm
|
10/12/2009 | SS | Market Commentary: Digital River likely to recover; Onyx seen on deal sidelines; PepsiCo delays not expected
|
8/7/2009 | CV | New Issue: Onyx prices $200 million of seven-year convertibles at 4%, up 30%
|
8/7/2009 | CV | Market Commentary: Onyx, Rayonier price rich, jump; D.R. Horton up with sector; Cubist gets pre-conference boost
|
8/6/2009 | CV | Onyx prices $200 million seven-year convertibles to yield 4%, up 30%
|
8/6/2009 | CV | Market Commentary: Onyx stays afloat in gray; Rayonier quiet; Alexandria, Virgin Media gain with earnings
|
8/5/2009 | CV | Market Commentary: Onyx up in gray; UAL boosted by oil, report; Transocean drops on results; Rayonier plans deal
|
8/4/2009 | CV | Onyx talks $200 million of seven-year convertibles at 4%-4.5%, up 20%-25% for Thursday
|
8/4/2009 | CV | Market Commentary: Hologic higher on earnings, forecast; Vale, Human Genome gain after upgrades; Onyx plans deal
|
8/29/2007 | SP | New Issue: ABN Amro sells $300,000 15.25% Knock-in Reverse Exchangeables linked to Onyx
|
8/2/2007 | SP | ABN Amro plans 15.25% Knock-in Reverse Exchangeables linked to Onyx
|
6/29/2007 | SP | New Issue: Barclays prices $1 million 11.65% reverse convertibles linked to Onyx Pharmaceuticals
|
6/18/2007 | CV | Onyx Pharmaceuticals files automatic shelf registration
|
6/8/2007 | SP | Barclays to price 11.65% reverse convertibles linked to Onyx
|
5/22/2007 | SP | Rabo to price 19.7% knock-in reverse convertibles linked to Onyx via LaSalle
|
5/15/2007 | SP | Market Commentary: Rabo plans 34.75% reverse convertibles linked to InterOil, 19.7% notes linked to Onyx Pharma
|
5/14/2007 | SP | Rabo to price 19.7% knock-in reverse convertibles linked to Onyx Pharmaceuticals via LaSalle
|
2/12/2007 | SS | Market Commentary: Four Seasons, Hilton, Starwood slide; Southwest soars; Eddie Bauer off; WCI up; Onyx rockets
|
11/9/2006 | BT | Onyx stays at neutral by Merrill
|
11/8/2006 | BT | Merrill neutral on Onyx
|
11/7/2006 | BT | Onyx has net loss of $20.1 million for the quarter, Nexavar revenue at $45.4 million
|
10/18/2006 | BT | Onyx continues to be driven by Nexavar
|
10/2/2006 | PP | Market Commentary: Accentia stock edges up after $25 million convertibles sale; GTC to close $25 million PIPE
|
9/29/2006 | BT | Market Commentary: Exelixis follow-on set for Oct. 2 week; ImaRx on tap; Biomira bounces; Labopharm, Pharmacopeia lower
|
9/29/2006 | PP | Market Commentary: Onyx Pharmaceuticals concludes $150 million equity line; Rancher Energy wraps $6.64 million PIPE
|
9/29/2006 | BTPP | New Issue: Onyx Pharmaceuticals obtains $150 million equity line
|
8/9/2006 | BT | Merrill keeps Onyx at neutral
|
8/9/2006 | BT | Market Commentary: Palatin up; Genaera gouged by reverse split plans; Onyx off; RegeneRx up; KOS up
|
7/24/2006 | BT | Nexavar approved by European Commission for the treatment of advanced kidney cancer
|
7/20/2006 | BT | Bayer, Onyx receive FDA fast-track designation for Nexavar for advanced melanoma treatment
|
6/8/2006 | BT | Onyx says combination therapies are Nexavar's future
|
6/6/2006 | BT | RBC rates Onyx at outperform
|
6/6/2006 | BT | Market Commentary: Xenoport deal emerges; Human Genome up 4%; Anadys, Idenix drop on HGSI news; Onyx up
|
6/5/2006 | BT | Onyx at outperform by RBC
|
6/5/2006 | BT | Merrill has Onyx at neutral
|
5/30/2006 | BTCVHY | Onyx Pharmaceuticals files $300 million shelf
|
5/3/2006 | BT | Bayer, Onyx finish enrollment in Nexavar phase 3 trials
|
5/3/2006 | BT | Onyx keeps neutral rating from Merrill
|
4/28/2006 | BT | Bayer, Onyx: European medicinal committee gives Nexavar positive recommendation in kidney cancer
|
4/28/2006 | BT | Merrill keeps Onyx at neutral
|
4/27/2006 | BT | Merrill has Onyx at neutral
|
4/26/2006 | BT | Bayer, Onyx granted orphan drug status for liver cancer drug Nexavar
|
3/30/2006 | BT | Bayer, Onyx drug Nexavar approved in Switzerland to treat patients with kidney cancer
|
2/17/2006 | BT | Onyx kept at neutral by Merrill
|
2/16/2006 | BT | Bayer, Onyx begin phase 3 non-small cell lung cancer trial of Nexavar tablets
|
2/16/2006 | BT | Merrill maintains Onyx at neutral
|
2/16/2006 | BT | Market Commentary: Adolor up on heavy volume after deal; Avigen sinks; Biogen, Elan react to Tysabri news; Onyx slips
|
2/16/2006 | BT | Market Commentary: Adolor up on heavy volume after deal; Avigen sinks; Biogen, Elan react to Tysabri news; Onyx slips
|
2/1/2006 | BT | Merrill maintains Onyx at neutral
|
1/27/2006 | BT | Merrill remains neutral on Onyx
|
1/12/2006 | BT | Market Commentary: OSI punishment over Eyetech buy continues; NPS up; PDL plunges; Genta; Favrille, Illumina all higher
|
12/22/2005 | BT | Onyx maintained by Merrill at neutral
|
12/21/2005 | BT | Merrill maintains Onyx at neutral
|
12/20/2005 | BT | Bayer, Onyx announce FDA approval of Nexavar tablets to treat kidney cancer
|
12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/18/2005 | BT | New Issue: Onyx raises $126.25 million in follow-on at $25.25, discounted from $25.38 close
|
11/17/2005 | BT | Market Commentary: Gilead off on reports of deaths; Onyx deal at bat; Durect rises on upgrade, but some buyers hesitate
|
11/14/2005 | BT | Onyx Pharma plans follow-on sale of 5 million shares via Morgan, Merrill this week
|
11/14/2005 | BT | Market Commentary: OSI, Eyetech tie knot; Genentech hits new high; SkyePharma soars on buyout interest; Onyx launches
|
11/4/2005 | BT | Merrill Lynch maintains Onyx at neutral
|
8/5/2005 | BT | Onyx Pharma estimates revised by Merrill
|
7/26/2005 | BT | Onyx cut by Bear Stearns to peer perform
|
7/21/2005 | BT | Onyx reiterated by Merrill at neutral
|
7/11/2005 | BT | Onyx maintained by Merrill at neutral
|
6/15/2005 | BT | Mylan Labs upgraded by Lehman
|
1/20/2005 | CV | Onyx Pharmaceuticals files $250 million shelf
|